Carbon monoxide ameliorates murine T-cell-dependent colitis through the inhibition of Th17 differentiation

References

• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641–1657.
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65–70.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen Z. Inflammatory bowel disease related innate immunity and adaptive immunity. Am J Transl Res. 2016;8(6):2490–2497.
   PubMed Web of Science ®Google Scholar
• Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology. 2008;134(4):1038–1048.
   PubMedGoogle Scholar
• Seiderer J, Elben I, Diegelmann J, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008;14(4):437–445.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 2008;57(12):1682–1689.
   PubMed Web of Science ®Google Scholar
• Naito Y, Takagi T, Higashimura Y. Heme oxygenase-1 and anti-inflammatory M2 macrophages. Arch Biochem Biophys. 2014;564:83–88.
   PubMed Web of Science ®Google Scholar
• Takagi T, Naito Y, Mizushima K, et al. Inhalation of carbon monoxide ameliorates TNBS-induced colitis in mice through the inhibition of TNF-alpha expression. Dig Dis Sci. 2010;55(10):2797–2804.
   PubMed Web of Science ®Google Scholar
• Takagi T, Naito Y, Uchiyama K, et al. Carbon monoxide liberated from carbon monoxide-releasing molecule exerts an anti-inflammatory effect on dextran sulfate sodium-induced colitis in mice. Dig Dis Sci. 2011;56(6):1663–1671.
   PubMed Web of Science ®Google Scholar
• Hegazi RA, Rao KN, Mayle A, et al. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med. 2005;202(12):1703–1713.
   PubMed Web of Science ®Google Scholar
• Sheikh SZ, Hegazi RA, Kobayashi T, et al. An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. J Immunol. 2011;186(9):5506–5513.
   PubMed Web of Science ®Google Scholar
• Ostanin DV, Bao J, Koboziev I, et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009;296(2):G135–G146.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Toyonaga T, Morita Y, et al. Efficacy of a new hemostatic forceps during gastric endoscopic submucosal dissection: a prospective randomized controlled trial. J Gastroenterol Hepatol. 2017;32(4):846–851.
   PubMed Web of Science ®Google Scholar
• Motterlini R, Sawle P, Hammad J, et al. CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule. FASEB J. 2005;19(2):284–286.
   PubMedGoogle Scholar
• Aranda R, Sydora BC, McAllister PL, et al. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol. 1997;158(7):3464–3473.
   PubMed Web of Science ®Google Scholar
• Takagi T, Naito Y, Higashimura Y, et al. Partially hydrolysed guar gum ameliorates murine intestinal inflammation in association with modulating luminal microbiota and SCFA. Br J Nutr. 2016;116(7):1199–1205.
   PubMed Web of Science ®Google Scholar
• Fukuda W, Takagi T, Katada K, et al. Anti-inflammatory effects of carbon monoxide-releasing molecule on trinitrobenzene sulfonic acid-induced colitis in mice. Dig Dis Sci. 2014;59(6):1142–1151.
   PubMed Web of Science ®Google Scholar
• Steiger C, Uchiyama K, Takagi T, et al. Prevention of colitis by controlled oral drug delivery of carbon monoxide. J Control Release. 2016;239:128–136.
   PubMed Web of Science ®Google Scholar
• Takagi T, Naito Y, Uchiyama K, et al. Colonic insufflation with carbon monoxide gas inhibits the development of intestinal inflammation in rats. Med Gas Res. 2012;2(1):23.
   PubMedGoogle Scholar
• Uddin MJ, Jeong SO, Zheng M, et al. Carbon monoxide attenuates dextran sulfate sodium-induced colitis via inhibition of GSK-3beta signaling. Oxid Med Cell Longev. 2013;2013:210563.
   PubMedGoogle Scholar
• Yin H, Fang J, Liao L, et al. Styrene-maleic acid copolymer-encapsulated CORM2, a water-soluble carbon monoxide (CO) donor with a constant CO-releasing property, exhibits therapeutic potential for inflammatory bowel disease. J Control Release. 2014;187:14–21.
   PubMed Web of Science ®Google Scholar
• Chora AA, Fontoura P, Cunha A, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest. 2007;117(2):438–447.
   PubMed Web of Science ®Google Scholar
• Listopad J, Asadullah K, Sievers C, et al. Heme oxygenase-1 inhibits T cell-dependent skin inflammation and differentiation and function of antigen-presenting cells. Exp Dermatol. 2007;16(8):661–670.
   PubMed Web of Science ®Google Scholar
• Moreau A, Hill M, Thébault P, et al. Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. FASEB J. 2009;23(9):3070–3077.
   PubMed Web of Science ®Google Scholar
• Rémy S, Blancou P, Tesson L, et al. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. J Immunol. 2009;182(4):1877–1884.
   PubMed Web of Science ®Google Scholar
• Simon T, Pogu S, Tardif V, et al. Carbon monoxide-treated dendritic cells decrease β1-integrin induction on CD8+ T cells and protect from type 1 diabetes. Eur J Immunol. 2013;43(1):209–218.
   PubMed Web of Science ®Google Scholar
• Nikolic I, Saksida T, Mangano K, et al. Pharmacological application of carbon monoxide ameliorates islet-directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects. Diabetologia. 2014;57(5):980–990.
   PubMed Web of Science ®Google Scholar
• Nikolic I, Vujicic M, Stojanovic I, et al. Carbon monoxide-releasing molecule-A1 inhibits Th1/Th17 and stimulates Th2 differentiation in vitro. Scand J Immunol. 2014;80(2):95–100.
   PubMed Web of Science ®Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–342.
   PubMed Web of Science ®Google Scholar
• Wallace KL, Zheng LB, Kanazawa Y, et al. Immunopathology of inflammatory bowel disease. World J Gastroenterol. 2014;20(1):6–21.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis. 2006;12(5):382–388.
   PubMed Web of Science ®Google Scholar
• Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004;110(1):55–62.
   PubMed Web of Science ®Google Scholar
• O’Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10(6):603–609.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135(4):1130–1141.
   PubMed Web of Science ®Google Scholar